Annexon presents positive Phase 2 data for ANX007 in GA; plans Phase 3 trials in 2024

Annexon, Inc.

ANX007 showed 73% relative risk reduction in BCVA 15-letter loss at 12 months in Phase 2 ARCHER trial.
Statistically significant slowing of low luminance visual acuity loss and reduction in photoreceptor loss observed.
No choroidal neovascularization increase and no cases of vasculitis; generally well-tolerated safety profile.
Global pivotal Phase 3 ARCHER II (vs sham) expected mid-2024; Phase 3 ARROW (vs SYFOVRE) expected H2 2024.
Preclinical data show C1q blockade protects photoreceptor synapses and preserves retinal function in GA models.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.